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Abstract: Vosaroxin, a quinolone-derivative chemotherapeutic agent, was considered a promising 
drug for the treatment of acute myeloid leukemia (AML). Early-stage clinical trials with this 
agent led to a large randomized double-blind placebo-controlled study of vosaroxin in combi-
nation with intermediate-dose cytarabine for the treatment of relapsed or refractory AML. The 
study demonstrated better complete remission rates with vosaroxin, but there was no statistically 
significant overall survival benefit in the whole cohort. A subset analysis censoring patients who 
had undergone allogeneic stem cell transplantation, however, revealed a modest but statisti-
cally significant improvement in overall survival particularly among older patients. This article 
reviews the data available on vosaroxin including clinical trials in AML and offers an analysis 
of findings of these studies as well as the current status of vosaroxin.
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Introduction
Acute myeloid leukemia (AML) comprises a heterogeneous group of hematologic 
malignancies characterized by expansion of clonal myeloid blasts in the bone marrow, 
blood, and other tissues. The American Cancer Society estimates the diagnosis of 
21,380 new AML cases and about 10,590 deaths from this disease in 2017.1 The 
incidence of AML increases with age, with median age of 67 years at diagnosis.1 
Moreover, age is a major prognostic factor in AML, with more dismal outcome in older 
individuals. Patients at the ages of 60–69, 70–79, and 80 years and older demonstrate 
5-year survival of 13%, 3%, and 0%, respectively.2
Unfortunately, despite intense research, little has changed in the effective treatment 
of AML over the past 3 decades. Induction chemotherapy with anthracyclines and 
cytarabine remains the standard approach for the first-line treatment of this disease. 
Many older patients are unable to tolerate such therapy and therefore considered 
ineligible for chemotherapeutic induction. Among those who receive induction 
chemotherapy, great majority will either not achieve a remission or experience relapse 
later. In addition, potential cardiotoxicity of anthracyclines has always been a concern, 
particularly in older population with higher incidence of underlying cardiovascular 
pathology. Hypomethylating agents, decitabine and azacitidine, have gained popularity 
for the treatment of older adults with AML due to their outpatient administration and 
assumed better tolerability. These agents, however, have not demonstrated superior 
long-term outcome compared with other approaches.3
Patients with relapsed or refractory AML, particularly older ones, suffer from an 
extremely unfavorable outcome with limited therapeutic options, small chance of 
achievement of a complete remission (CR), and short median overall survival (OS).4 
Cytarabine monotherapy or cytarabine-containing combination regimens are usually 
administered as salvage therapy in those considered candidates for intense therapy, 
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offering low CR rates, short remission duration, and high 
toxicity. A recent international study treating patients with 
relapsed or refractory AML with several regimens reported 
only about 20% CR rate.5
Several clinical trials have studied different agents for the 
treatment of older patients with AML, but none has shown 
a definitive improvement in outcome. Vosaroxin, a chemo-
therapeutic agent, has demonstrated some promising results 
in this patient population but was not able to gain approval 
from the US Food and Drug Administration (FDA) for 
clinical use. This article reviews the available clinical data 
on the treatment of AML with this agent.
Structure and function of vosaroxin
Vosaroxin (formerly SNS-595) is an anticancer quinolone-
derivative chemotherapeutic agent with a naphthyridine 
core similar to quinolone antibiotics.6 Vosaroxin does not 
have antibacterial activity, but demonstrates cytotoxicity in 
the cancer cell lines.7 This cytotoxicity is exerted through 
two major mechanisms, inhibition of type II topoisomerase 
and intercalation into the DNA.8 Type II topoisomerases 
are essential for the cell survival. These enzymes maintain 
normal DNA topology and chromosome condensation by 
constant disentangling of knotted over-wound DNA that 
is formed during replication process.9 Poisoning of type II 
topoisomerase would be catastrophic to actively replicating 
cells, resulting in cell death. Anthracyclines are chemothera-
peutic agents known for their topoisomerase II poisoning 
activity. There are two limitations; however, to the clini-
cal applicability of these agents, they 1) are subject to the 
P-glycoprotein receptor-mediated efflux pump that actively 
throws them out of the cell, 2) can cause myocardial cell 
injury resulting in cardiotoxicity mainly due to the induction 
of intracellular reactive oxygen species (ROS).10,11 When 
tested in cell lines, vosaroxin activity was not subject to 
P-glycoprotein pump.7 In addition, cell-based studies have 
demonstrated that vosaroxin does not generate significant 
ROS, therefore is less likely to cause dose-dependent 
cardiotoxicity.6 Vosaroxin intercalates into DNA at spe-
cific G/C-rich sites.8 Incorporation of vosaroxin into DNA 
also induces DNA damage, G2-phase cell cycle arrest, and 
S-phase prolongation which will lead to cell apoptosis.6,8,9 
The property of vosaroxin inducing DNA damage at specific 
G/C-rich regions might translate into a less mutagenic effect 
on normal cells compared with anthracyclines which exhibit 
a nonspecific DNA intercalation.6
Vosaroxin has shown favorable pharmacokinetic proper-
ties in rat and monkey, and it is believed to be less cardiotoxic 
than anthracyclines in human beings.12 In addition, vosaroxin-
induced apoptosis is p53 independent; therefore, it may evade 
p53-dependent drug resistance.7 Finally, since vosaroxin is 
minimally metabolized by enzymatic processes, it may be 
less subject to interaction with other drugs.13
Preclinical data
Vosaroxin has demonstrated cytotoxic activity in tumor 
models. A tumor growth inhibition of 63%–88% was 
observed in murine syngeneic tumor models of Lewis lung 
carcinoma, M5076 ovarian sarcoma, and colon 26 and xeno-
graft models of ovarian, breast, colon, gastric, and melanoma 
lung cancers, as well as two hematologic malignancies.7 
Vosaroxin combined with cytarabine demonstrated additive 
or synergistic activity on acute leukemia cell lines HL-60 
(acute promyelocytic leukemia) and MV4-11 (AML).14 
A suggested explanation for the enhanced activity of this 
combination is that vosaroxin exerts its effect after the 
cytarabine-induced DNA damage that makes vulnerable cells 
exit the S-phase and enter the G2-phase.14
Phase I study
A Phase Ib dose-escalation study evaluated pharmacokinetics 
and safety of vosaroxin and established the maximum tol-
erated dose (MTD) and dose-limiting toxicities (DLTs) in 
patients with relapsed or refractory leukemia.15 Approxi-
mately 85% of patients had AML, 78% with refractory 
disease. Vosaroxin dose was escalated in both a weekly 
schedule for 3 weeks (days 1, 8, 15) and a twice-weekly 
schedule for 2 weeks (days 1, 4, 8, 11). A total of 73 patients 
(median age 65 years) were treated. In the weekly schedule, 
42 patients received vosaroxin 18–90 mg/m2 and the MTD 
was 72 mg/m2. In the twice-weekly schedule, 31 patients 
received vosaroxin 9–50 mg/m2 and the MTD was deter-
mined at 40 mg/m2. The DLT was stomatitis. Primary non-
hematologic toxicities were gastrointestinal symptoms and 
neutropenic fever. Other frequent non-hematologic toxicities 
that occurred in .30% of patients, but were not dose limiting, 
included fatigue, anorexia, peripheral edema, and dyspnea. 
Vosaroxin demonstrated linear pharmacokinetic proper-
ties over the dose range of 9–90 mg/m2 when administered 
once or twice weekly. The average terminal half-life of the 
drug was about 25 hours, and the clearance was non-renal. 
No induction or inhibition of vosaroxin metabolism was 
observed. Evidence of DNA damage was confirmed through 
the detection of elevated intracellular γH2AX, a product of 
histone phosphorylation in response to DNA breaks. Five 
patients (7%) achieved a CR or CR with incomplete platelet 
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recovery (CRp), of whom four were on weekly and one on 
the twice-weekly treatment schedule.
Phase II studies in AML
ReveAL-1: single-agent vosaroxin in 
older population
This Phase II trial evaluated vosaroxin in patients aged 
60 years or older with previously untreated AML.16 Eligibility 
criteria required at least one of the following: age 70 years or 
older, intermediate or unfavorable cytogenetics, or an ante-
cedent hematologic disorder. The weekly regimen was opted 
for, and a dose optimization was pursued through sequential 
cohorts (A: 72 mg/m2, days 1, 8, 15; B: 72 mg/m2, days 1, 8; 
C: 72 mg/m2 [C72] or 90 mg/m2 [C90], days 1, 4). A total of 
113 patients received at least one induction therapy, among 
them 26 (23%) required a second induction due to residual 
disease on the day 14 marrow. Grade 3/4 hematologic 
toxicities including neutropenic fever were frequent (50%). 
Grade 3/4 infections had higher incidence with schedule 
A (76%) than with the other three schedules (B: 57%; C72: 
48%; C90: 55%). Grade $3 (bacterial, fungal, or viral) sepsis 
occurred in 39% of patients, with lowest frequency in the 
schedule C72 cohort. The most frequent non-hematologic 
toxicities included gastrointestinal (diarrhea 74%, nausea 
70%, stomatitis 60%) and metabolic effects (hypokalemia 
62%, anorexia 59%, hypomagnesemia 43%). The incidences 
of diarrhea, stomatitis, hypokalemia, and anorexia were lower 
with schedules B and C than with schedule A. A total of 
91 patients (81%) had $1 serious adverse event (SAE). The 
most common SAEs included pneumonia (24%), neutropenic 
fever (21%), and stomatitis (10%). Of 113 patients, 103 died 
over the study period. A total of 80 deaths (78%) were due 
to progressive disease. All-cause mortality rates were 12% 
and 31% within first 30 and 60 days, respectively. Lowest 
mortality rate was seen in schedule C72: 7% and 17% 30- and 
60-day mortality, respectively.
CR/CRp was achieved in 36 patients (32%), with 33 CRs 
(29%). The highest CR/CRp rates occurred with schedules 
A (41%) and C72 (35%). Most remissions (28 of 36, 78%) 
occurred with one induction therapy. A total of 26 patients 
received a second induction course, of whom eight (31%) 
obtained a CR/CRp. The median OS for all patients was 
7 months (95% CI, 4.0–9.2 months) with 8.6 and 7.7 months 
for schedules A and C72, respectively. A 1-year survival rate of 
38% was reported with both schedules A and C72. The median 
OS of the 36 responders (CR and CRp) was 15.5 months 
(95% CI, 12.7–18.3 months), with a median leukemia-free 
survival (LFS) of 6.5 months (95% CI, 4.9–9.8 months).
Schedule C72 exhibited the most favorable safety and 
efficacy, with faster hematologic recovery (median 27 days) 
and lowest incidence of aggregate sepsis (24%) and 30- and 
60-day all-cause mortality (7% and 17%, respectively). For 
this group, CR was 31%, CR/CRp was 35%, median OS was 
7.7 months, and 1-year OS was 38%.
Combination of vosaroxin and cytarabine 
in relapsed/refractory AML
A combination of vosaroxin and cytarabine was assessed 
in a Phase Ib/II study in patients with relapsed or refractory 
AML.17 Escalating doses of vosaroxin (10-minute infusion; 
10–90 mg/m2; days 1, 4) were given with cytarabine on one of 
two schedules: schedule A (24-hour continuous intravenous 
[IV] infusion; 400 mg/m2/day; days 1–5) or schedule B (2-hour 
IV infusion; 1 g/m2/day; days 1–5). A total of 56 patients on 
schedule A and 52 on schedule B received at least one dose 
of vosaroxin and/or cytarabine. In schedule A, the MTD of 
vosaroxin was 80 mg/m2 (DLTs: grade 3 stomatitis and bowel 
obstruction lasting more than 7 days). The MTD was not 
reached for schedule B. The highest vosaroxin dose tested on 
schedule B was 90 mg/m2, which was selected for Phase III 
study. The most common non-hematologic toxicities were 
diarrhea (76%), hypokalemia (73%), nausea (67%), and 
stomatitis (66%). Among the 108 treated patients across both 
schedules, 24 (22%) achieved a CR, and the combined CR 
and CRp was observed in 28 patients (26%). The 30- and 
60-day all-cause mortality rates were 2.5% (2/78) and 9.0% 
(7/78), respectively, among patients treated at MTD or rec-
ommended Phase II dose. Mortality rate was 2% in 30 days 
and 8% in 60 days for all patients on schedule B.
Phase III VALOR study
Findings of previous trials led to the design of a Phase III 
randomized double-blind trial named VALOR (Vosaroxin 
and Ara-C combination EvaLuating Overall Survival in 
Relapsed/Refractory AML).18 Patients were randomized 1:1 
to receive cytarabine (1 g/m2/day IV for 5 days) plus either 
vosaroxin (90 mg/m2 IV first cycle; 70 mg/m2 subsequently) 
or placebo on days 1 and 4. Patients older than 18 with 
AML in first relapse or with refractory disease were eligible. 
Relapsed disease was defined as recurrence between 90 days 
and 24 months after first remission. Persistent disease at 
least 28 days following the initiation of induction therapy 
and relapse within 90 days of first remission were consid-
ered refractory disease. All patients should have received 
anthracycline- and cytarabine-containing induction therapy 
previously, and a maximum of two previous induction 
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therapies were allowed. All molecular and cytogenetic 
subtypes were eligible. Patients with left ventricular ejection 
fraction of less than 40% and those who had received 
cytarabine at a total dose of 5 g/m2 or more within 90 days 
of randomization were ineligible.
A total of 711 patients were enrolled and randomized; 
of whom, 705 received treatment (355 vosaroxin and 
350 placebo). All 711 patients were included in the efficacy 
analysis, while the safety analysis was conducted on the 
750 treated patients. A total of 148 patients (21%) required a 
second induction therapy due to residual AML in the day 14 
marrow (70 [20%] in the vosaroxin arm and 78 [22%] in the 
placebo arm). A total of 97 patients (27%) in the vosaroxin 
group and 50 (14%) in the placebo group received at least 
one consolidation cycle, while up to two consolidations were 
allowed. A total of 210 (30%) patients underwent allogeneic 
stem cell transplantation. The number of transplanted patients 
was similar between the two arms, 107 (30%) and 103 (29%) 
in the vosaroxin and placebo groups, respectively. However, 
as expected, a considerably higher number of patients 
younger than 60 years received transplantation as opposed 
to those aged 60 years or older (46% vs 20%).
SAEs including neutropenic fever, infection, and gas-
trointestinal mucosal toxicity were more common in the 
vosaroxin arm (33%) than in the placebo arm (17%). Rate 
of cardiac toxicities was same in both arms, including atrial 
fibrillation at 6% and 7% in the placebo and vosaroxin arms, 
respectively, and one myocardial infarction in the vosaroxin 
arm. Short-term all-cause mortality rates were similar with 
8% vs 7% 30-day mortality and 20% vs 19% 60-day mortality 
in the vosaroxin vs placebo groups, respectively.
CR and CRp were achieved in 38% and 19% of patients on 
the vosaroxin and placebo arms, respectively. The difference 
in remission rate was more pronounced in the older age group 
of 60 years and above. Among patients who achieved a CR, 
the median LFS was 11.0 months in the vosaroxin group vs 
8.7 months in the placebo group (P=0.63).
The median OS was not statistically different between the 
two groups (7.5 months in the vosaroxin group and 6.1 months 
in the placebo group; P=0.061). A predefined analysis, how-
ever, that censored patients who had received allogeneic stem 
cell transplantation, demonstrated a 1.4-month longer OS in 
the vosaroxin group (median 6.7 vs 5.3 months; P=0.027). 
The difference in OS was greatest in patients aged 60 years 
or older (7.1 vs 5.0 months; P=0.003) and in those with 
early relapse (6.7 vs 5.2 months; P=0.039). The OS was not 
significantly different between the treatment arms in younger 
patients, refractory cases, or those with late relapse.
Discussion
Minimal improvement has been made over the past few decades 
in the treatment of relapsed or refractory AML. While most 
salvage regimens incorporate a potentially cardiotoxic anthra-
cycline or anthracenedione, vosaroxin, a chemotherapeutic 
agent with possibly less cardiotoxic effect, represents a promis-
ing outlook. The drug underwent standard experimental steps, 
including Phase I, II, and III studies, for the treatment of patients 
with relapsed or refractory AML. Table 1 summarizes the clini-
cal trials with this agent and their outcome. Vosaroxin, either 
as single agent or in combination with cytarabine, was found 
tolerable within acceptable safety profile even in older patients. 
Based on early-phase studies, vosaroxin was deemed worthy of 
moving forward to a large randomized Phase III trial.
The VALOR trial was a large multi-institutional study 
that followed all necessary rules of a double-blind random-
ized clinical trial. One critique to the design of this study 
would be selection of the comparison arm, ie, a cytarabine 
dose of 1 g/m2/day for 5 days. Intermediate-dose cytarabine is 
commonly used in combination with other agents in salvage 
regimens such as mitoxantrone, etoposide, and cytarabine 
(MEC) or fludarabine, cytarabine, granulocyte colony stimu-
lating factor, and iradubicin (FLAG-Ida). However, with a 
total dosing of 5 mg/m2, single-agent cytarabine may have 
represented a suboptimal induction attempt.
Remission rates were superior in the vosaroxin/cytarabine 
arm compared with single-agent cytarabine. However, it 
remains unclear if vosaroxin/cytarabine could stand non-
inferior to higher total doses of cytarabine or commonly 
used combination regimens such as MEC or FLAG-Ida. 
An argument in support of vosaroxin would be possible better 
tolerability of vosaroxin/cytarabine than other regimens, at 
least in the older population.
The higher remission rate with vosaroxin/cytarabine, 
however, did not translate into a better long-term outcome. 
Despite the potentially suboptimal comparison arm, VALOR 
study failed to demonstrate statistically significant prolon-
gation of OS in favor of vosaroxin. Subsequent analysis of 
data, censoring patients who had undergone allogeneic stem 
cell transplantation, revealed a modest improvement in OS 
of 1.4 months with vosaroxin that reached statistical signifi-
cance. Such finding may reflect lack of long-term efficacy 
of transplant in this patient population regardless of salvage 
regimen used for induction. It may also be interpreted as pos-
sible higher efficacy of vosaroxin in older population, since 
the number of transplanted patients was significantly greater 
among those below the age of 60 years. Indeed, the difference 
in OS in favor of vosaroxin reached statistical significance 
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among patients older than 60 years (7.1 vs 5.0 months in 
the vosaroxin/cytarabine vs cytarabine arms, respectively; 
P=0.0030). In addition, a post hoc analysis revealed an OS 
benefit in patients with unfavorable-risk cytogenetics and 
FLT3 mutations which collectively comprise the most poor-
risk subtypes of AML.
Cardiotoxicity, particularly in older individuals, remains 
a major concern with the use of anthracyclines. Myocardial 
cell injury by ROS is believed to be one of the major mecha-
nisms of anthracycline-induced cardiotoxicity.11 Although 
there exists a wide interindividual variability, studies have 
shown that the risk of cardiomyopathy increases dramati-
cally from less than 0.3% up to 7% once the cumulative 
anthracycline dose exceeds 500–550 mg/m2 of doxorubicin 
or equivalent.19 Considering the fact that cumulative dose of 
anthracyclines usually remains below this cutoff level after a 
typical induction chemotherapy at initial diagnosis and one 
re-induction therapy for relapsed/refractory disease, indeed 
the incidence of anthracycline-induced cardiomyopathy in 
real practice remains minimal. Moreover, cardiomyopathy is 
usually a long-term complication of anthracyclines, occurring 
after months or years of exposure, while great majority of 
older AML patients never enjoy a survival long enough to 
experience such delayed toxicity. In practice, therefore, the 
traditionally feared anthracycline-induced cardiomyopathy 
is seen very uncommonly in adults with AML, who mostly 
belong to an older age group. Nevertheless, since vosaroxin 
exposure induces generation of less significant amount of 
Table 1 Clinical studies using vosaroxin
Study Patient 
no/disease
Treatment Toxicity Outcome
Phase ib15 73
Re/Re
A: v weekly ×3
B: v twice weekly ×2
Neutropenic fever
Stomatitis
Gi
MTD group A: 90 mg/m2
MTD group B: 40 mg/m2
CR/CRp 7%
Phase ii16 (ReveAL-1) 113
Untreated
A: v 72 mg/m2 weekly ×2
B: v 73 mg/m2 weekly ×3
C: v 72 mg/m2, d 1, 4
D: v 90 mg/m2, d 1, 4 
Neutropenic fever
Stomatitis
Gi (nausea, diarrhea)
CR/CRp 32%
MOS of responders 15.5 mo
30-/60-day all-cause mortality 12/31%
Phase ib/ii17 
(combination)
108
Re/Re
A: v 10–90 mg/m2, d 1, 4
+ Cy 400 mg/m2/d Civ, d 1–5
B: v 10–90 mg/m2, d 1, 4
+ Cy 1 g/m2/d, d 1–5
Stomatitis
Nausea
Diarrhea
MTD group A: 80 mg/m2
MTD group B: not achieved
CR/CRp 26%
MOS 6.9 mo
30-/60-day all-cause mortality 2.5/9%
Randomized20 104
Untreated
v 72 mg/m2, d 1, 4
vs
LDAC 20 mg BiD, d 1–10
Gi (stomatitis/diarrhea) 
significantly worse in the V arm
CR/CRp v vs LDAC
26% vs 30%; P=0.7
12-mo survival v vs LDAC
12% vs 31%; P=0.003 
Randomized20 104
Untreated
v 72 mg/m2, d 1, 4+ LDAC 
20 mg BiD, d 1–10
vs
LDAC 20 mg BiD, d 1–10
Gi (stomatitis/diarrhea) 
significantly worse in the V + 
LDAC arm
CR/CRp v + LDAC vs LDAC
38% vs 34%; P=0.6
12-mo survival v + LDAC vs LDAC
33% vs 37%; P=0.3
Phase iii18
Double-blind, 
randomized (vALOR)
705
Re/Re
v 90 mg/m2, d 1, 4
+ Cy 1 g/m2/d; d 1–5
vs
placebo
+ Cy 1 g/m2/d; d 1–5
Neutropenic fever, infection, Gi:
v + Cy 33%
Placebo + Cy 17%
CR/CRp v + Cy vs placebo + Cy
38% vs 19%
MOS v + Cy vs placebo + Cy
All patients:
7.5 vs 6.1 mo; P=0.06
Censored for allotransplant:
6.7 vs 5.3 mo; P=0.027
Patients aged 60 years and older:
7.1 vs 5.0 mo; P=0.003
early relapsed patients:
6.7 vs 5.2 mo; P=0.039
30-day all-cause mortality
v + Cy vs placebo + Cy 8% vs 7% 
60-day all-cause mortality
v + Cy vs placebo + Cy 20% vs 19%
Abbreviations: BiD, twice daily; Civ, continues intravenous infusion; CR, complete remission; CRp, CR with incomplete platelet recovery; Cy, cytarabine; d, day; Gi, 
gastrointestinal; LDAC, low-dose Ara-C; mo, months; MOS, median overall survival; MTD, maximum tolerated dose; Re/Re, relapsed/refractory; v, vosaroxin.
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ROS, it is expected to cause less myocardial cell injury than 
anthracyclines. As an inclusion criterion, patients enrolled 
in VALOR study were required to have adequate baseline 
cardiac function, defined as left ventricular ejection fraction 
of 40% or greater.18 With a median follow-up of 24.4 months, 
VALOR study did not report cardiomyopathy among patients 
who had received vosaroxin. It is unclear from the report 
whether or not, and how, these patients were monitored for 
possible delayed cardiac toxicity. Nevertheless, vosaroxin 
appears to have less potential for cardiotoxicity than anthra-
cyclines, and thus portrays a more attractive agent.
Two randomized trials in previously untreated AML 
conducted in the UK reported significant gastrointestinal 
toxicities with vosaroxin at a dose of 72 mg/m2.20 In neither 
of these studies, the vosaroxin arm demonstrated a superior 
outcome, and the authors concluded that the lack of benefit 
was mostly due to increased early mortality associated 
with this agent. It is to be noted, however, that both studies 
enrolled patients who were not considered suitable for 
intensive therapy. These patients therefore would have been 
at higher risk of complications or mortality with myelosup-
pressive chemotherapy. In the abovementioned Phase Ib/II 
study of vosaroxin/cytarabine, the MTD was reached in 
schedule A at vosaroxin dose of 80 mg/m2.16 Collectively, 
these findings signal for potential clinically significant 
toxicity with vosaroxin at doses of 72 mg/m2 and above. 
In VALOR study, response rates, including CR and CRp, 
were significantly higher in the vosaroxin/cytarabine group, 
and also there was higher early mortality attributed to adverse 
events in this group. We can conclude that the long-term 
OS benefit of vosaroxin may have been more prominent if 
vosaroxin-related toxicities could have been reduced or better 
controlled so a reduction in early mortality achieved. Thus, 
for future consideration of AML treatment with this drug, 
a cautious dose modification to avoid significant toxicities 
while preserving efficacy seems essential. Preparation for 
more vigorous supportive care would also be important to 
reduce toxicity-related morbidity and mortality. It is to be 
noted that the 90 mg/m2 dose of vosaroxin in the VALOR 
study was chosen based on highest dose used in previous 
Phase II trial of vosaroxin/cytarabine combination, and not 
necessarily for a proven higher efficacy. Hence, one may 
speculate that lower doses, perhaps below 72 mg/m2, may 
be as efficacious but less toxic.
In conclusion, multiple studies have shown the efficacy 
of vosaroxin, particularly in combination with intermediate-
dose cytarabine, in the treatment of AML. In a large ran-
domized study, however, the drug did not demonstrate OS 
benefit, possibly due to severe toxicities resulting in increased 
early mortality. A more cautious use of the drug with con-
sideration of appropriate dose modification may overcome 
unacceptable toxicity while keeping the desirable efficacy. It 
appears, at least in the relapsed/refractory setting, that the drug 
may be more promising in the age group of 60 years and older 
in early relapse, and those with unfavorable-risk cytogenetics 
or FLT3 mutations. Indeed, the most unmet need in the treat-
ment of AML is focused on these exact patient populations. 
Appropriate patient selection and cautious dosing may be key 
for success in future applications of this drug. In addition, 
further clinical trials with vosaroxin in other settings such as 
previously untreated AML would be reasonable. Currently, 
vosaroxin is not approved in the USA by FDA for clinical use 
in AML. Vosaroxin in combination with infusional cytarabine 
or hypomethylating agents is in clinical trials for the treatment 
of AML and high-risk myelodysplastic syndromes.
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